The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO.
 
Sylvie Lorenzen
Honoraria - Lilly
Consulting or Advisory Role - Celgene; Lilly; MSD Oncology; Sanofi/Aventis; SERVIER
Research Funding - Lilly
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck KGaA; MSD; Nordic Drugs; Pfizer; Roche
Research Funding - Merck; Novartis
Travel, Accommodations, Expenses - Astellas Oncology; Bristol-Myers Squibb; Lilly; Merck; Roche; Teva
 
Claudia Pauligk
No Relationships to Disclose
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pfizer; Roche Pharma AG; Sanofi
Travel, Accommodations, Expenses - SERVIER
 
Thomas Jens Ettrich
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Pfizer; Sanofi; Sanofi; Sirtex Medical
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Florian Lordick
Honoraria - AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Infomedica; Lilly; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; SERVIER
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Michael Stahl
Honoraria - Amgen; Celgene; Lilly; Merck; Roche; Sanofi; Shire
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Lilly; MSD
Travel, Accommodations, Expenses - Amgen; Lilly; Merck
 
Peter Reichardt
Honoraria - Bayer; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - ARIAD; Clinigen Group; Lilly; Merck; Novartis; Pfizer; PharmaMar; Roche
Research Funding - Novartis (Inst)
 
Martin Soekler
No Relationships to Disclose
 
Daniel Pink
Employment - Helios Kliniken GmbH
Consulting or Advisory Role - Clinigen Group; Lilly; Roche
Research Funding - Clinigen Group (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
 
Stephan Probst
No Relationships to Disclose
 
Hana Algül
Honoraria - Celgene; SERVIER
Consulting or Advisory Role - Celgene
 
Axel Hinke
Stock and Other Ownership Interests - Lilly
 
Thorsten Oliver Goetze
Honoraria - Bayer; Celgene; Lilly; MSD; Servier; Shire
Consulting or Advisory Role - Bayer; Celgene; Lilly; MSD; Servier; Shire
Speakers' Bureau - Lilly; Miami Cancer Institute; MSD
Research Funding - German Research Foundation
 
Salah-Eddin Al-Batran
Leadership - IKF Klinische Krebsforschung
Stock and Other Ownership Interests - IKF Klinische Krebsforschung
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; MCI group; Nordic Bioscience; Promedior; Roche
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma